No association between whole-body ultraviolet A1 phototherapy and skin cancers in humans: a cancer registry linkage study
- 1 September 2020
- journal article
- letter
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 183 (3), 586-587
- https://doi.org/10.1111/bjd.19041
Abstract
Ultraviolet A1 (UVA1) phototherapy was first developed in the 1980s.1 Its use started in the UK in Dundee in 1996.2 It is not available in most centres despite being useful for some of the sclerosing/fibrosing conditions and granulomatous conditions. Where available, for some individuals, it can be very helpful for other indications such as atopic eczema.3 A concern is that sufficient exposures might increase the risk of skin cancer.4 Itt has been shown to produce cyclobutane‐pyrimidine dimers in humans,5 and so has the potential to be carcinogenic.This publication has 7 references indexed in Scilit:
- UVA1 Induces Cyclobutane Pyrimidine Dimers but Not 6-4 Photoproducts in Human Skin In VivoJournal of Investigative Dermatology, 2012
- Ultraviolet A1 phototherapy: a British Photodermatology Group workshop reportClinical and Experimental Dermatology, 2012
- UVA1 is skin deep: molecular and clinical implicationsPhotochemical & Photobiological Sciences, 2012
- Merkel cell carcinoma arising in immunosuppressed patients treated with high-dose ultraviolet A1 (320-400 nm) phototherapy: a report of two casesPhotodermatology, Photoimmunology & Photomedicine, 2010
- Ultraviolet A1 phototherapyBritish Journal of Dermatology, 2003
- Assoziation zwischen UVA1 bzw. Bade-PUVA-Bestrahlung und Melanomentwicklung?Die Dermatologie, 2001
- A New Apparatus with High Radiation Energy Between 320–460 nm: Physical Description and Dermatological ApplicationsJournal of Investigative Dermatology, 1981